JPMorgan Chase & Co. Increases Holdings in Haleon plc (NYSE:HLN)

JPMorgan Chase & Co. lifted its position in Haleon plc (NYSE:HLN) by 25.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 5,084,202 shares of the company’s stock after purchasing an additional 1,026,939 shares during the period. JPMorgan Chase & Co.’s holdings in Haleon were worth $53,791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp lifted its holdings in Haleon by 13.7% in the second quarter. Bank of New York Mellon Corp now owns 1,572,542 shares of the company’s stock valued at $12,989,000 after acquiring an additional 189,519 shares during the period. Allspring Global Investments Holdings LLC lifted its stake in shares of Haleon by 249.4% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 17,704 shares of the company’s stock worth $146,000 after purchasing an additional 12,637 shares during the period. Natixis Advisors LLC boosted its holdings in shares of Haleon by 10.8% in the second quarter. Natixis Advisors LLC now owns 607,697 shares of the company’s stock worth $5,020,000 after buying an additional 59,099 shares during the last quarter. Rhumbline Advisers grew its position in Haleon by 20.0% during the second quarter. Rhumbline Advisers now owns 48,966 shares of the company’s stock valued at $404,000 after buying an additional 8,160 shares during the period. Finally, Advisor OS LLC purchased a new stake in Haleon during the second quarter valued at approximately $83,000. 6.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on HLN. Morgan Stanley lifted their price target on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research note on Friday, September 20th. UBS Group upgraded Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. One research analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $10.95.

Haleon Stock Performance

HLN opened at $9.46 on Friday. The company has a 50 day simple moving average of $9.64 and a two-hundred day simple moving average of $9.65. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58. The firm has a market cap of $42.82 billion, a P/E ratio of 27.82, a PEG ratio of 2.95 and a beta of 0.28. Haleon plc has a 1-year low of $7.89 and a 1-year high of $10.80.

About Haleon

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.